How Much Does Wegovy Cost in Wisconsin in 2026?

Wisconsin Retail Pricing for Wegovy

The average cash-pay price for Wegovy across Wisconsin retail pharmacies sits at $1,349 per month in 2026, matching Novo Nordisk's manufacturer list price. This figure reflects the cost for the maintenance dose of 2.4 mg administered once weekly by subcutaneous injection.

Prices can shift modestly between pharmacy chains. Costco and independent pharmacies in Milwaukee, Madison, and Green Bay sometimes post prices $20 to $50 below the list figure, though availability fluctuates with supply. The FDA-approved prescribing information for Wegovy outlines a five-step dose-escalation schedule starting at 0.25 mg weekly, reaching the full 2.4 mg maintenance dose at month five. During escalation months, pen costs may differ slightly based on the specific dose strength dispensed.

Without insurance or discount programs, a full year of Wegovy at maintenance dose runs approximately $16,188. That figure puts the medication out of reach for many Wisconsin residents paying entirely out of pocket, which makes understanding insurance pathways and alternative pricing options worth the effort [1].

Wisconsin Medicaid Coverage

Wisconsin Medicaid does cover Wegovy, but the program requires prior authorization before dispensing. This means a prescriber must document that the patient meets specific clinical criteria before the state's Medicaid program will pay for the drug.

Typical PA requirements include a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prescriber generally must also document that the patient has attempted lifestyle modifications (diet and exercise) for a defined period, often three to six months, before pharmacotherapy approval.

Wisconsin's ForwardHealth program processes these authorizations. Approval periods commonly run six to twelve months, with renewals contingent on the patient demonstrating measurable weight loss (typically 5% or more of baseline body weight). The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity supports the use of semaglutide 2.4 mg as a first-line pharmacotherapy option for adults with obesity, giving prescribers a strong evidence basis for PA submissions [2].

Patients denied on initial PA can appeal. A letter of medical necessity from the prescribing clinician that references trial data and guideline recommendations increases the likelihood of a successful appeal.

Commercial Insurance Coverage in Wisconsin

Coverage among private insurers varies widely. Some of the largest employers in Wisconsin, including those in the healthcare and manufacturing sectors, have added GLP-1 receptor agonists for weight management to their formularies since 2024. Others still classify Wegovy as a non-covered "lifestyle" medication.

Plans that do cover Wegovy often place it on a specialty tier, which means copays can range from $150 to $500 per month even with coverage. The specific tier placement and copay amount depend on the plan design. Patients should check their plan's formulary or call the number on the back of their insurance card to confirm coverage status and any PA requirements.

Self-insured employer plans, which cover a large share of Wisconsin's commercially insured population, make their own formulary decisions independent of state insurance mandates. A 2023 analysis published in JAMA Network Open found that fewer than 50% of large employer plans covered anti-obesity medications, though that percentage has been climbing [3].

Wisconsin-based health systems such as UW Health and Advocate Aurora have established obesity medicine clinics with staff experienced in navigating insurance authorizations for GLP-1 medications. Patients struggling with denials may benefit from referral to these programs.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card program that can reduce Wegovy costs to $0 per month for eligible patients with commercial insurance. The program has specific eligibility rules that Wisconsin patients should understand before relying on it.

Eligible patients must have commercial (private) insurance that covers Wegovy. The savings card covers the remaining copay or coinsurance up to a maximum monthly benefit, currently capped at $500 per 28-day supply. Patients with government insurance, including Medicare Part D, Medicaid, TRICARE, and VA benefits, are not eligible for the savings card.

To activate the card, patients can visit the Novo Nordisk patient assistance website or call their dedicated support line. The card is presented at the pharmacy alongside the insurance card at the time of each fill. Pharmacists in Wisconsin are familiar with processing these cards, though first fills may take a few extra minutes at the counter.

For uninsured patients, Novo Nordisk also operates a Patient Assistance Program (PAP) that provides Wegovy at no cost to qualifying individuals with household incomes below 400% of the federal poverty level. Application requires documentation of income and a prescription from a licensed provider [1].

Compounded Semaglutide 2.4 mg in Wisconsin

Compounded semaglutide 2.4 mg is available in Wisconsin through licensed 503A compounding pharmacies at an average cost of approximately $199 per month. That price represents an 85% reduction compared to the brand-name product.

A 503A pharmacy compounds medications pursuant to individual patient prescriptions under the oversight of state boards of pharmacy. Wisconsin law permits 503A compounding, and the Wisconsin Pharmacy Examining Board regulates these facilities. Compounded semaglutide is prepared as a sterile injectable formulation, matching the subcutaneous route of the branded product.

The legal status of compounded semaglutide has been a subject of federal attention. The FDA maintains a drug shortage list that has included semaglutide products at various points since 2022. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may compound copies of commercially available drugs when those drugs appear on the shortage list. As supply conditions change, the legal basis for compounding may shift. Patients and prescribers should verify current shortage status before initiating compounded semaglutide [4].

Quality varies between compounding pharmacies. Patients should confirm that their 503A pharmacy holds current state licensure, undergoes third-party potency and sterility testing, and can provide certificates of analysis for each batch. The FDA's guidance on compounding outlines the regulatory framework that governs these pharmacies [5].

Clinical Evidence Behind Wegovy

The efficacy of semaglutide 2.4 mg for chronic weight management rests on a large body of clinical trial data. Understanding what the drug actually delivers helps Wisconsin patients weigh the cost against expected outcomes.

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg once weekly achieved a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group. The trial enrolled adults with a BMI of 30 or greater (or 27 or greater with at least one comorbidity) without diabetes. More than 86% of semaglutide-treated participants lost at least 5% of their body weight, and one-third lost 20% or more [6].

Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine and STEP-1 investigator, stated: "The magnitude of weight loss seen with semaglutide 2.4 mg exceeds what we have historically achieved with any other single anti-obesity medication" [6].

The SELECT trial (N=17,604) demonstrated cardiovascular benefit beyond weight loss. Participants with established cardiovascular disease and overweight or obesity but without diabetes who received semaglutide 2.4 mg experienced a 20% reduction in major adverse cardiovascular events (MACE) over a median follow-up of 39.8 months. This result led to an expanded FDA indication for cardiovascular risk reduction in March 2024 [7].

The American Association of Clinical Endocrinology (AACE) 2024 consensus statement notes: "Semaglutide 2.4 mg should be considered as a first-line pharmacotherapy for adults with obesity, particularly those with cardiovascular comorbidities" [8].

Telehealth Access in Wisconsin

Wisconsin permits telehealth prescribing of Wegovy. Patients can consult with licensed prescribers via video or audio visits and receive a prescription sent electronically to their preferred Wisconsin pharmacy, including mail-order options.

Several telehealth platforms now serve Wisconsin residents specifically for weight management. These platforms typically charge a consultation fee ranging from $50 to $199, with some offering monthly membership models that bundle the prescriber visit with ongoing monitoring and dose adjustments.

Wisconsin's telehealth parity law requires commercial insurers to cover telehealth services at the same rate as in-person visits for the same service. This means the consultation itself should be covered under most plans, though the medication cost remains a separate line item subject to the plan's pharmacy benefit [9].

Patients using telehealth should confirm that their prescriber holds an active Wisconsin medical license or practices under interstate licensure compact rules. The prescriber should also be willing to order baseline labs, including a hemoglobin A1c, lipid panel, and thyroid function tests, before initiating semaglutide. The Endocrine Society guidelines recommend screening for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 before prescribing any GLP-1 receptor agonist [2].

How to Reduce Your Wegovy Costs in Wisconsin

Multiple strategies exist for lowering out-of-pocket spending on Wegovy in the state. The right approach depends on insurance status and income.

Commercially insured patients should first confirm formulary coverage, then apply for the Novo Nordisk savings card. If Wegovy is not covered, ask the prescriber to submit a PA with supporting documentation from the STEP-1 and SELECT trials. Appeal any denial with a letter of medical necessity.

Wisconsin Medicaid patients should work with their prescriber to complete the PA process. Document BMI, comorbidities, and prior lifestyle modification attempts thoroughly. If denied, request a fair hearing through the ForwardHealth member services line.

Uninsured patients have two main options. The Novo Nordisk Patient Assistance Program provides brand-name Wegovy at no cost for qualifying low-income individuals. Compounded semaglutide 2.4 mg from a licensed Wisconsin 503A pharmacy costs approximately $199 per month and requires a valid prescription [4][5].

Medicare Part D patients face the most limited options. Medicare Part D does not cover anti-obesity medications, and patients cannot use the Novo Nordisk savings card. Congressional legislation to add obesity drug coverage to Medicare has been introduced but not enacted as of May 2026. Compounded semaglutide represents the most affordable pathway for Medicare beneficiaries seeking this therapy.

Comparison shopping between pharmacies can also yield savings. GoodRx and RxSaver discount cards may reduce cash prices by $50 to $100 at certain Wisconsin retailers, though these discounts cannot be combined with insurance or manufacturer cards.

Side Effects and Monitoring Considerations

Cost discussions should account for the monitoring and management that Wegovy requires. The most common adverse effects in clinical trials were gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) at the 2.4 mg dose [1].

These side effects are dose-dependent, which is why the prescribing information mandates a 16-week dose-escalation schedule. Starting at 0.25 mg and increasing every four weeks allows most patients to develop tolerance. In STEP-1, fewer than 7% of participants discontinued semaglutide due to gastrointestinal adverse events [6].

Prescribers should monitor for signs of pancreatitis, gallbladder disease, and changes in heart rate. The FDA label carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though this risk has not been confirmed in humans. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use Wegovy [1].

Follow-up visits every three to six months are standard during maintenance therapy. Labs including a metabolic panel and lipid profile help track cardiometabolic improvements that often accompany weight loss with semaglutide. These monitoring costs, typically covered by insurance, add $100 to $300 annually for uninsured patients.